|Awarded On||August 24, 2018|
|Title||Combination Drug Therapy for Cutaneous T-Cell Lymphoma|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Kerry Barnhart|
*Pending contract negotiation
CerRx, Inc. is a west Texas-based company developing a new drug for treating cancer with better effectiveness and fewer side-effects than current treatments. CerRx’s lead drug candidate, intravenous (IV) fenretinide, has been shown in human clinical trials to be particularly effective in treating T-cell lymphomas (in some cases completely abolishing the cancers), while having fewer side-effects than other drug used for treating such tumors. CerRx has one currently open clinical trial to further test IV fenretinide on one type of T-cell lymphoma, peripheral T-cell lymphoma (PTCL), a cancer than can case tumors to form anywhere in the body.
CerRx is now proposing to conduct a similar clinical t...